Home > Boards > US Listed > Miscellaneous > ZIOPHARM Oncology Inc (ZIOP)

It appears that the Company does not have

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Plegee Member Profile
 
Followed By 2
Posts 113
Boards Moderated 0
Alias Born 08/17/06
160x600 placeholder
 ISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Management’s WHITE Consent Card Business Wire - 11/25/2020 8:30:00 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/24/2020 4:46:01 PM
WaterMill Asset Management Sets the Record Straight Following Ziopharm’s Apparent Attempt to Mislead Shareholders & Rewrite... Business Wire - 11/24/2020 9:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/23/2020 5:24:16 PM
Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Share... GlobeNewswire Inc. - 11/20/2020 11:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/20/2020 6:01:35 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/19/2020 4:49:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 4:47:21 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/19/2020 4:14:47 PM
WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology Business Wire - 11/19/2020 9:30:00 AM
White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology PR Newswire (US) - 11/19/2020 9:00:00 AM
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2... GlobeNewswire Inc. - 11/19/2020 9:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/18/2020 5:17:22 PM
Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer GlobeNewswire Inc. - 11/17/2020 4:15:00 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/16/2020 2:49:22 PM
Ziopharm Oncology Appoints Mary Thistle to Board of Directors GlobeNewswire Inc. - 11/16/2020 8:30:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/13/2020 4:57:06 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/12/2020 3:08:10 PM
WaterMill Asset Management Releases Candid Q&As with Each of its Director Candidates for Election to Ziopharm Oncology’s Bo... Business Wire - 11/12/2020 9:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2020 5:17:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:09:46 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 4:04:00 PM
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders Business Wire - 11/5/2020 9:05:00 AM
Proxy Statement - Non-management (definitive, Revised) (dfrn14a) Edgar (US Regulatory) - 11/4/2020 4:10:11 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/2/2020 5:18:48 PM
Plegee   Sunday, 06/28/20 06:02:35 PM
Re: None
Post # of 1139 
It appears that the Company does not have the shareholder votes to re-elect the Board of Directors nor approve the ridiculous compensation management is getting. We will know tomorrow (if not postponed). I hope all proposals fail. Cooper is not CEO material, not even senior manager level of any kind. Never invest in a biotech with an MD at the helm, never; no matter how promising. So many clinical deadlines have passed, so many promises broken, no urgency to get things done; no fiduciary sense of any kind, no shareholder accountability. All this without a modicum of explanation of any kind to the shareholders. The ridiculous secondary of four months ago was the last straw, literally conceding to shorts by allowing them to `invest' and cover. . . . the same people who have tried to bankrupt this company for the last five years.

The company may take a $$ hit on this but will ultimately be placed in more competent hands; we can not get any worse decision making than present. We have no idea after five years of what, if any, of this `ground breaking' technology clinically works. Clearly there are issues with the NCI. Programs invested in five years ago just drop off the company radar with no comment by management. Worst company I have ever encountered. Millions of bonuses and compensation to Cooper over the years and he has not once bought a single share in this company; just the recipient of endless gifts. Complete disgrace. Don't want him as CMO either. Carl June to the rescue please.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences